Osr Holdings Inc (OSRH)

$0.36 -0.01 (-2.22%)
Market Cap 13.75M
Revenue (ttm) 2.91M
Net Income (ttm) -27.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -929.90%
Debt to Equity Ratio 0.04
Volume 320,882
Avg Vol 7,733,460
Day's Range N/A - N/A
Shares Out 35.11M
Stochastic %K 3%
Beta 0.61
Analysts Strong Buy
Price Target N/A

Company Profile

OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 635 7700
Address:
10900 NE 4th Street, Suite 2300, Bellevue, United States
KeepItRealistic
KeepItRealistic Jun. 25 at 4:25 AM
$OSRH difficult to take overnight trading seriously when there are only two trades of 1 share each šŸ˜ šŸ‘‡
0 Ā· Reply
KeepItRealistic
KeepItRealistic Jun. 25 at 3:41 AM
$OSRH it will come ā€¦ From last PR šŸ‘‡ ā€œManagement is evaluating partnerships, subsidiary monetizations, spin-offs, other actions to unlock shareholder value.ā€
0 Ā· Reply
Basana09
Basana09 Jun. 25 at 2:57 AM
$OSRH iā€™m wanting to buy, but so afraid of an RS. This shit needs some good news here. Good luck to all.
0 Ā· Reply
Thedoe111
Thedoe111 Jun. 25 at 12:09 AM
$OSRH
1 Ā· Reply
Frog007
Frog007 Jun. 25 at 12:08 AM
$OSRH looks like our CEO is professional in scamming othersChardan Capital Markets' lawsuit alleges that OSR Holdings and CEO Kuk Hyoun Hwang breached their advisory contract by failing to pay $2,070,000 in cash and 34,500 shares of deferred equity. The suit seeks personal liability for Hwang and compensation for damages, with the court recently ordering the CEO to be deposed by June 26, 2026, and a status conference set for July 9, 2026
1 Ā· Reply
IldijanaMM
IldijanaMM Jun. 24 at 11:44 PM
$OSRH Hello Mr attacker now even you lost the trust šŸ¤£ I need a apologize from you!
0 Ā· Reply
IldijanaMM
IldijanaMM Jun. 24 at 11:43 PM
$OSRH I would say his lies! Promises of no R/S and the meeting with out R/S on table that he postponed is scam and manipulation this deserve to be at 0.05$ right now! Tomorrow say goodbye to 30s folks šŸ˜ŽšŸ¤„
0 Ā· Reply
hitlist0
hitlist0 Jun. 24 at 11:35 PM
$OSRH damn its red everyday and making new lows all happened after that CEO back to back useless PRs
0 Ā· Reply
ZdP2
ZdP2 Jun. 24 at 10:45 PM
$OSRH Our best chance to pump (in the short term) is the Woori deal with Samsung coming to fruition. It could happen. Otherwise it's a long term dilution play gamble with some hope of a spike somewhere...
0 Ā· Reply
CelestialSurfing
CelestialSurfing Jun. 24 at 8:54 PM
$OSRH A few things to keep in mind that I did not consider before investing (dummy). 1.) Cash on hand end of Q1 was only enough runway for ~1.5 months. 2.) $15M put option for liquidity is locked out until end of October. 3.) To get us through 4-5 months they will need to print conservatively 15 million shares. The major risk: If they donā€™t meet NASDAQ compliance the put option becomes void. A couple observations: 1.) The idea that shorts are causing the recent price action is negligent and misleading to fellow investors. 2.) Reverse Split is likely on the table as being NASDAQ compliant is a final lifeline to key funding. Additional $815M payments are only expected later 2027 as phase 2 data comes in.
3 Ā· Reply
Latest News on OSRH
OSR Holdings changes corporate name to OSR Health

2026-06-22T13:28:55.000Z - 2 days ago

OSR Holdings changes corporate name to OSR Health

OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do

Jun 22, 2026, 9:06 AM EDT - 2 days ago

OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do

CEO Statement to Shareholders

Jun 3, 2026, 12:05 PM EDT - 21 days ago

CEO Statement to Shareholders

OSR Holdings acquires full VXM01 intellectual property portfolio for $30M

2026-05-27T15:40:49.000Z - 4 weeks ago

OSR Holdings acquires full VXM01 intellectual property portfolio for $30M

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

May 27, 2026, 9:06 AM EDT - 4 weeks ago

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

OSR Holdings CEO says company not pursuing reverse stock split

2026-05-12T19:35:00.000Z - 6 weeks ago

OSR Holdings CEO says company not pursuing reverse stock split

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

May 5, 2026, 1:05 PM EDT - 7 weeks ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

Apr 30, 2026, 9:15 AM EDT - 7 weeks ago

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings enters $815M global license agreement for VXM01 with BCM Europe

2026-04-29T16:28:46.000Z - 2 months ago

OSR Holdings enters $815M global license agreement for VXM01 with BCM Europe

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

Apr 29, 2026, 9:50 AM EDT - 2 months ago

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings eliminates $2.02M warrant overhang

2026-04-09T13:34:34.000Z - 2 months ago

OSR Holdings eliminates $2.02M warrant overhang

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

Apr 9, 2026, 9:15 AM EDT - 2 months ago

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Mar 30, 2026, 9:00 AM EDT - 3 months ago

OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

Mar 27, 2026, 9:00 AM EDT - 3 months ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings announces update to $815M VXM01 licensing deal structure

2026-03-23T12:46:05.000Z - 3 months ago

OSR Holdings announces update to $815M VXM01 licensing deal structure

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

Mar 23, 2026, 8:30 AM EDT - 3 months ago

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

OSR Holdings subsidiary signs NDA with Sinopharm

2026-03-19T13:07:19.000Z - 3 months ago

OSR Holdings subsidiary signs NDA with Sinopharm

OSR Holdings subsidiary signs NDA with Sinopharm

2026-03-19T13:07:07.000Z - 3 months ago

OSR Holdings subsidiary signs NDA with Sinopharm

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

Mar 19, 2026, 8:55 AM EDT - 3 months ago

Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities

OSR Holdings granted 180-day Nasdaq extension

2026-03-05T14:44:08.000Z - 3 months ago

OSR Holdings granted 180-day Nasdaq extension

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

Mar 5, 2026, 9:30 AM EST - 3 months ago

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

OSR Holdings completes Woori IO acquisition

2026-01-27T13:50:45.000Z - 5 months ago

OSR Holdings completes Woori IO acquisition

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Jan 27, 2026, 8:30 AM EST - 5 months ago

OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Jan 22, 2026, 9:55 AM EST - 5 months ago

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Vaximm Appoints SĆ©bastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Jan 16, 2026, 9:20 AM EST - 5 months ago

Vaximm Appoints SĆ©bastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Jan 12, 2026, 8:05 AM EST - 5 months ago

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

OSR Holdings announces Woori IO shareholders approve share exchange

2025-12-19T16:55:10.000Z - 6 months ago

OSR Holdings announces Woori IO shareholders approve share exchange

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Dec 19, 2025, 11:50 AM EST - 6 months ago

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Dec 4, 2025, 3:19 PM EST - 7 months ago

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Vaximm updates term sheet with BCM Europe to shorten exclusivity period

2025-12-02T15:06:23.000Z - 7 months ago

Vaximm updates term sheet with BCM Europe to shorten exclusivity period

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Dec 2, 2025, 9:53 AM EST - 7 months ago

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

Dec 1, 2025, 3:01 PM EST - 7 months ago

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

OSR Holdingsā€™ Vaximm AG enters non-binding term sheet with BCM Europe

2025-11-21T14:25:17.000Z - 7 months ago

OSR Holdingsā€™ Vaximm AG enters non-binding term sheet with BCM Europe

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Nov 21, 2025, 9:20 AM EST - 7 months ago

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

Nov 14, 2025, 11:10 AM EST - 7 months ago

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

OSR Holdingsā€™ glucose monitor demonstrates accuracy and precision in pilot study

2025-11-06T13:48:10.000Z - 8 months ago

OSR Holdingsā€™ glucose monitor demonstrates accuracy and precision in pilot study

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

Nov 6, 2025, 8:30 AM EST - 8 months ago

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

Oct 20, 2025, 11:39 AM EDT - 8 months ago

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to acquire Woori IO for needle-free glucose monitoring

2025-10-14T12:41:26.000Z - 9 months ago

OSR Holdings to acquire Woori IO for needle-free glucose monitoring

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

Oct 14, 2025, 8:30 AM EDT - 9 months ago

OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

OSR Holdings receives non-compliance letter from Nasdaq

2025-09-09T21:35:11.000Z - 10 months ago

OSR Holdings receives non-compliance letter from Nasdaq

OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

Sep 9, 2025, 5:30 PM EDT - 10 months ago

OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

Aug 1, 2025, 1:29 PM EDT - 11 months ago

OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

OSR Holdings Provides Transparency Update on Equity Financing Instruments

Jul 31, 2025, 12:45 PM EDT - 11 months ago

OSR Holdings Provides Transparency Update on Equity Financing Instruments

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

Jul 30, 2025, 4:10 PM EDT - 11 months ago

OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure

OSR Holdings to acquire glucose monitoring provider Woori IO

2025-07-24T11:41:06.000Z - 11 months ago

OSR Holdings to acquire glucose monitoring provider Woori IO

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

Jul 24, 2025, 7:30 AM EDT - 11 months ago

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

Jul 15, 2025, 7:30 AM EDT - 1 year ago

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

Jul 9, 2025, 7:58 AM EDT - 1 year ago

OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG

OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

May 22, 2025, 7:36 AM EDT - 1 year ago

OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

May 2, 2025, 7:30 AM EDT - 1 year ago

Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

Apr 9, 2025, 7:54 AM EDT - 1 year ago

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

Apr 3, 2025, 7:30 AM EDT - 1 year ago

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Mar 26, 2025, 7:16 AM EDT - 1 year ago

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

OSR Holdings Appoints Dr. Constance Hƶfer as Chief Scientific Officer

Mar 25, 2025, 7:00 AM EDT - 1 year ago

OSR Holdings Appoints Dr. Constance Hƶfer as Chief Scientific Officer

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

Feb 14, 2025, 6:10 PM EST - 1 year ago

OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination

KeepItRealistic
KeepItRealistic Jun. 25 at 4:25 AM
$OSRH difficult to take overnight trading seriously when there are only two trades of 1 share each šŸ˜ šŸ‘‡
0 Ā· Reply
KeepItRealistic
KeepItRealistic Jun. 25 at 3:41 AM
$OSRH it will come ā€¦ From last PR šŸ‘‡ ā€œManagement is evaluating partnerships, subsidiary monetizations, spin-offs, other actions to unlock shareholder value.ā€
0 Ā· Reply
Basana09
Basana09 Jun. 25 at 2:57 AM
$OSRH iā€™m wanting to buy, but so afraid of an RS. This shit needs some good news here. Good luck to all.
0 Ā· Reply
Thedoe111
Thedoe111 Jun. 25 at 12:09 AM
$OSRH
1 Ā· Reply
Frog007
Frog007 Jun. 25 at 12:08 AM
$OSRH looks like our CEO is professional in scamming othersChardan Capital Markets' lawsuit alleges that OSR Holdings and CEO Kuk Hyoun Hwang breached their advisory contract by failing to pay $2,070,000 in cash and 34,500 shares of deferred equity. The suit seeks personal liability for Hwang and compensation for damages, with the court recently ordering the CEO to be deposed by June 26, 2026, and a status conference set for July 9, 2026
1 Ā· Reply
IldijanaMM
IldijanaMM Jun. 24 at 11:44 PM
$OSRH Hello Mr attacker now even you lost the trust šŸ¤£ I need a apologize from you!
0 Ā· Reply
IldijanaMM
IldijanaMM Jun. 24 at 11:43 PM
$OSRH I would say his lies! Promises of no R/S and the meeting with out R/S on table that he postponed is scam and manipulation this deserve to be at 0.05$ right now! Tomorrow say goodbye to 30s folks šŸ˜ŽšŸ¤„
0 Ā· Reply
hitlist0
hitlist0 Jun. 24 at 11:35 PM
$OSRH damn its red everyday and making new lows all happened after that CEO back to back useless PRs
0 Ā· Reply
ZdP2
ZdP2 Jun. 24 at 10:45 PM
$OSRH Our best chance to pump (in the short term) is the Woori deal with Samsung coming to fruition. It could happen. Otherwise it's a long term dilution play gamble with some hope of a spike somewhere...
0 Ā· Reply
CelestialSurfing
CelestialSurfing Jun. 24 at 8:54 PM
$OSRH A few things to keep in mind that I did not consider before investing (dummy). 1.) Cash on hand end of Q1 was only enough runway for ~1.5 months. 2.) $15M put option for liquidity is locked out until end of October. 3.) To get us through 4-5 months they will need to print conservatively 15 million shares. The major risk: If they donā€™t meet NASDAQ compliance the put option becomes void. A couple observations: 1.) The idea that shorts are causing the recent price action is negligent and misleading to fellow investors. 2.) Reverse Split is likely on the table as being NASDAQ compliant is a final lifeline to key funding. Additional $815M payments are only expected later 2027 as phase 2 data comes in.
3 Ā· Reply
KeepItRealistic
KeepItRealistic Jun. 24 at 8:37 PM
$OSRH all you need here are shares & patience šŸ‘‡
0 Ā· Reply
KeepItRealistic
KeepItRealistic Jun. 24 at 8:36 PM
$OSRH all you need here are shares & patience šŸ‘‡
0 Ā· Reply
Rebirth_Coldblooded
Rebirth_Coldblooded Jun. 24 at 8:25 PM
$OSRH whatā€™s worse, is BCM will flip this drug as quickly as possible, so there will be no residuals from it. Our best chance to pump is trials, and the longer this goes without it, means no one is interested in funding it, or OSRH has no interest in helping clear the regulatory hurdles needed
0 Ā· Reply
Rebirth_Coldblooded
Rebirth_Coldblooded Jun. 24 at 8:22 PM
$OSRH share buybacks with what money? These people are diluting to keep the lights on. They need funding but BCM needs to clear regulatory hurdles or pay the 10 share price in October for 15m. We donā€™t see any of that but it gives them a runway. They are selling shares thru Lion, anytime they want. This bleeds until phase3 trials are funded. Woori is a pipe dream.
0 Ā· Reply
IldijanaMM
IldijanaMM Jun. 24 at 7:47 PM
$OSRH Closing my short at 0.2 for a pump to 0.38 on some bullshit news letter from CEO this is how you make money here folks. Follow for more money not bullshit like some here put out! CEO lied and now we play the game this shit stock is!
0 Ā· Reply
KeepItRealistic
KeepItRealistic Jun. 24 at 7:46 PM
$OSRH thank you to the short sighted !
0 Ā· Reply
IldijanaMM
IldijanaMM Jun. 24 at 7:27 PM
$OSRH Short it and make money or Sell and never look back CEO is a lying biaach
0 Ā· Reply
StockQueenB
StockQueenB Jun. 24 at 7:24 PM
$OSRH they need news asap. Share buyback all kinds of good news it'll shoot to $3 possibly depending on what it is
1 Ā· Reply
stefangl
stefangl Jun. 24 at 7:14 PM
$OSRH well, I donā€™t know how are we getting $1, but we need some good news soon!
0 Ā· Reply
Roland115
Roland115 Jun. 24 at 7:11 PM
$OSRH āœ…
0 Ā· Reply
Stay_Tuned_
Stay_Tuned_ Jun. 24 at 7:05 PM
$OSRH watching and waiting. Not selling core position.
0 Ā· Reply
Carter123456
Carter123456 Jun. 24 at 7:02 PM
$OSRH holy shit
0 Ā· Reply